Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Sales | 686 | 193 | 37 | 75 | 75 |
| Gross Profit | 686 | 193 | 37 | 75 | 75 |
| Operating Expenses | 35,605 | 35,855 | 35,816 | 30,791 | 26,916 |
| Operating Income | -34,919 | -35,662 | -35,779 | -30,716 | -26,841 |
| Interest Expense | 0 | 44 | 19 | 104 | 141 |
| Other Income | 839 | 669 | -108 | 169 | 108 |
| Pre-tax Income | -34,080 | -35,037 | -35,906 | -30,651 | -26,874 |
| Net Income Continuous | -34,080 | -35,037 | -35,906 | -30,651 | -26,874 |
| Net Income | $-34,080 | $-35,037 | $-35,906 | $-30,651 | $-26,874 |
| EPS Basic Total Ops | -0.94 | -0.97 | -1.16 | -1.01 | -0.90 |
| EPS Basic Continuous Ops | -0.94 | -0.97 | -1.15 | -1.01 | -0.90 |
| EPS Diluted Total Ops | -0.94 | -0.97 | -1.16 | -1.01 | -0.90 |
| EPS Diluted Continuous Ops | -0.94 | -0.97 | -1.15 | -1.01 | -0.90 |
| EBITDA(a) | $-34,857 | $-35,527 | $-35,379 | $-30,286 | $-26,344 |